A preclinical study led by Cedars-Sinai has identified UBE2N enzyme MASH research as a credible new direction, finding that the enzyme UBE2N may slow the progression of one of the most common and difficult-to-treat liver conditions. The study was published in Nature Metabolism.
An estimated 100 million people in the United States have metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease, according to the American Liver Foundation. Roughly 20% to 25% of those affected go on to develop metabolic dysfunction-associated steatohepatitis (MASH), a more serious form in which excess liver fat is accompanied by inflammation, cell injury and scarring. Current care mainly centres on lifestyle changes and limiting further liver damage. Medications are available, but treatment options remain limited and there is no cure.
What the UBE2N findings show
The multicenter study found that levels of UBE2N decline in liver cells as MASH becomes more advanced. Earlier research had suggested that damaged mitochondria, the structures that produce energy for cells, may contribute to the development and progression of MASH. The Cedars-Sinai-led team found that UBE2N appears to work in part by helping cells clear away those damaged mitochondria and supporting the breakdown of fat.
‘The UBE2N enzyme appears to protect the liver from the inflammation and damage associated with MASH by helping remove damaged mitochondria and supporting the breakdown of fat,’ said Ekihiro Seki, MD, PhD, professor of Medicine and Biomedical Sciences at Cedars-Sinai and co-corresponding author of the study. ‘When levels of the enzyme fell, we saw more damaged cells and injury to the liver.’
The researchers then restored UBE2N to normal levels in the livers of laboratory mice. After doing so, they observed reductions in fat accumulation, inflammation and scarring. Those results suggest that UBE2N could become a potential treatment target for preventing MASLD from advancing to MASH. The distinction matters: the move from MASLD to MASH is where serious, potentially irreversible liver injury begins.
UBE2N enzyme MASH research in wider context
Shelly Lu, MD, the Women’s Guild Chair in Gastroenterology and director of the Karsh Division of Gastroenterology and Hepatology at Cedars-Sinai, was measured about what comes next. ‘Future studies can test whether enhancing this protective pathway can complement existing treatments, identify patients most likely to benefit and lead to new therapeutic approaches for preventing advanced disease,’ she said. The framing is careful: this is a preclinical study, and the path from mouse model to licensed therapy is long and frequently does not complete.
That said, the broader field is moving. UC San Diego Health has reported that researchers there identified a drug candidate called ION224, which targets a different enzyme and has already progressed into clinical trials. In a Phase IIb trial involving 160 adults, 60% of participants receiving the highest dose of ION224 showed notable improvements in liver health compared with the placebo group, according to UC San Diego Health. That result does not establish ION224 as a standard of care, but it demonstrates that enzyme-targeting strategies for MASH can produce measurable clinical signals in human subjects, which is where the Cedars-Sinai preclinical work has not yet arrived.
The distinction is worth holding: UBE2N’s protective role has been observed in laboratory mice, and the study’s authors describe it as identifying a potential treatment target, not a therapy. The ION224 data, meanwhile, comes from a controlled trial in people, which carries different evidentiary weight. Both lines of research point toward enzymes as a plausible avenue in MASH, but they are at different stages and involve different mechanisms.
The Cedars-Sinai study received funding from, among others, the National Institutes of Health and the National Research Foundation of Korea. The paper is published in Nature Metabolism, volume 8, issue 9, with Ekihiro Seki listed as co-corresponding author alongside Yoon Seok Roh. The next step the authors name is future studies testing whether enhancing the UBE2N pathway can complement existing MASH treatments and help identify which patients are most likely to benefit.
